教室紹介

2019年業績集

受賞

  1. 欧州泌尿器科学会ベストポスター賞
    H. Fukushima, T. Kijima, M. Toide, S. Fukuda, S. Moriyama, Y. Yasuda, S. Uehara, S. Yoshida, M. Yokoyama, J. Ishioka, Y. Matsuoka, K. Saito, K. Kihara, Y. Fujii. Tetra-modality bladder sparing therapy can be a viable treatment option for muscle-invasive bladder cancer patients with sarcopenia. "Best Poster Presentation", The 34th Annual Congress of the European Association of Urology, Barcelona, Spain, 2019/3/18

  2. 欧州泌尿器科学会ベストポスター賞
    S. Yoshida, R. Takazawa, Y. Waseda, T. Tsujii. The significance of intraoperative renal pelvic urine and stone culture for patients at high risk of post-ureteroscopy systemic inflammatory response syndrome. "Best Poster Presentation", The 34th Annual Congress of the European Association of Urology, Barcelona, Spain, 2019/3/16

  3. 第107回日本泌尿器科学会総会 総会賞
    内田 裕將, 吉田 宗一郎, 下田 海生, 田中 宏, 阪本 剛, 上原 翔, 安田 庸輔, 木島 敏樹, 横山 みなと, 石岡 淳一郎, 松岡 陽, 齋藤 一隆, 藤井 靖久. 拡散強調MRIのwhole-lesion ADC 解析を用いた嫌色素性腎癌と腎オンコサイトーマの鑑別. 第107回日本泌尿器科学会総会 2019年4月19日

  4. 第59回日本産科婦人科内視鏡学会学術講演会　学会賞（論文部門）
    森山 真吾, 松浦 拓人, 沢田 勇吾, 林 篤正, 黄 鼎文, 常盤 紫野, 野村 昌良, 清水 幸子. 腹腔鏡下仙骨腟固定術における組織間腔を意識した後壁剥離法. 第59回日本産科婦人科内視鏡学会学術講演会 2019年9月13日

  5. 第5回日本泌尿器腫瘍学会学術集会 学術集会奨励賞
    木島 敏樹, 安田 庸輔, 上原 翔, 吉田 宗一郎, 横山 みなと, 石岡 淳一郎, 松岡 陽, 齋藤 一隆, 藤井 靖久. 筋層浸潤膀胱癌に対する4者併用膀胱温存療法(TUR+低用量化学放射線療法+膀胱部分切除). 第5回日本泌尿器腫瘍学会学術集会 2019年10月26日

原著

  1. Kawamura N, Yokoyama M, Tanaka H, Nakayama T, Yasuda Y, Kijima T, Yoshida S, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Acute kidney injury and intermediate-term renal function after clampless partial nephrectomy. Int J Urol, 26(1): 113-118, 2019.PubMed

  2. Tanaka H, Wang Y, Suk-Ouichai C, Palacios DA, Caraballo ER, Ye Y, Remer EM, Li J, Abouassaly R, Campbell SC. Can We Predict Functional Outcomes after Partial Nephrectomy? J Urol, 201(4): 693-701, 2019.PubMed

  3. Waseda Y, Saito K, Ishikawa Y, Kawano K, Yokoyama M, Ishioka J, Matsuoka Y, Morimoto S, Kihara K, Fujii Y. Predictive ability of renal cortex enhancement in dynamic computed tomography for residual renal function after nephroureterectomy: Comparison with 99m Tc-diethylenetriaminopentacetic acid renography and validation study. Int J Urol, 26(2): 266-272, 2019.PubMed

  4. Araki S, Kijima T, Waseda Y, Komai Y, Nakanishi Y, Uehara S, Yasuda Y, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Nakano Y, Yoshimoto T, Uchida T, Fujii Y. Incidence and predictive factors of hypoglycemia after pheochromocytoma resection. Int J Urol, 26(2): 273-277, 2019. PubMed

  5. Kijima T, Tanaka H, Koga F, Masuda H, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Selective Tetramodal Bladder Preservation Therapy Incorporating Induction Chemoradiotherapy and Consolidative Partial Cystectomy with Pelvic Lymph Node Dissection for Muscle-Invasive Bladder Cancer: Oncological and Functional Outcomes of 107 Patients. BJU Int, 124(2): 242-250, 2019.PubMed

  6. Yajima S, Yoshida S, Takahara T, Arita Y, Tanaka H, Waseda Y, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Usefulness of the inchworm sign on DWI for predicting pT1 bladder cancer progression. Eur Radiol, 29(7): 3881-3888, 2019.PubMed

  7. Yoshida S, Maeda T, Yokoyama M, Toide M, Saito K, Fujii Y. Application of eye tracking as a user interface for urological surgery. Int J Urol, 26(6): 680-681, 2019.PubMed

  8. Yoshida S, Sugimoto M, Fukuda S, Taniguchi N, Saito K, Fujii Y. Mixed reality computed tomography-based surgical planning for partial nephrectomy using a head-mounted holographic computer. Int J Urol, 26(6): 681-682, 2019.PubMed

  9. Yoshida S, Takazawa R, Uchida Y, Kohno Y, Waseda Y, Tsujii T. The significance of intraoperative renal pelvic urine and stone cultures for patients at a high risk of post-ureteroscopy systemic inflammatory response syndrome. Urolithiasis, 47(6): 533-540, 2019. PubMed

  10. Kobayashi M, Tanaka H, Tateishi U, Numao N, Yonese J, Ito M, Koga F, Fukushima H, Uehara S, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma. Int J Urol, 26(8): 820-826, 2019.PubMed

  11. Arita Y, Takahara T, Yoshida S, Kwee TC, Yajima S, Ishii C, Ishii R, Okuda S, Jinzaki M, Fujii Y. Quantitative Assessment of Bone Metastasis in Prostate Cancer Using Synthetic Magnetic Resonance Imaging. Invest Radiol, 54(10): 638-644, 2019.PubMed

  12. Yoshida S, Takahara T, Arita Y, Ishii C, Uchida Y, Nakagawa K, Toda K, Sakamoto T, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Yoshimura R, Fujii Y. Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer: Localization of the Progressive Site as a Prognostic Factor. Int J Radiat Oncol Biol Phys, 105(2): 376-381, 2019.PubMed

  13. Toide M, Yokoyama M, Fujiwara M, Kijima T, Saito K, Fujii Y. Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and partial cystectomy. Int J Urol, 26(10): 1010-1012, 2019.PubMed

総説

  1. Fukushima H, Fujii Y, Koga F. Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma. Int J Mol Sci, 20(3): 760, 2019.PubMed

  2. Kijima T, Prince T, Neckers L, Koga F, Fujii Y. Heat shock factor 1 (HSF1)-targeted anticancer therapeutics: overview of current preclinical progress. Expert Opin Ther Targets, 23(5): 369-377, 2019.PubMed

学会発表

欧州泌尿器科学会（34th European Association of Urology annual congress, Barcelona, Spain）

  1. Y. Matsuoka, S. Uehara, S. Yoshida, K. Tanabe, H. Tanaka, T. Kimura, S. Moriyama, Y. Yasuda, T. Kijima, M. Yokoyama, J. Ishioka, K. Saito, Y. Fujii. Who gains additional benefits from systematic biopsy concurrently performed with MRI-ultrasound fusion targeted biopsy in the detection of significant prostate cancer? 2019/3/16

  2. Y. Matsuoka, H. Tanaka, T. Kimura, S. Moriyama, S. Uehara, Y. Yasuda, T. Kijima, S. Yoshida, M. Yokoyama, J. Ishioka, K. Saito, Y. Fujii. Apparent diffusion coefficient ratio between tumor and nontumor as a potential imaging biomarker for prostate cancer. 2019/3/16

  3. J. Ishioka, M. Kobayashi、M. Fujiwara, N. Kawamura, T. Okuno, Y. Fukuda, T. Kohno, K. Kawano, S. Morimoto, S. Uehara, Y. Yasuda, T. Kijima, S. Yoshida, M. Yokoyama, M. Matsuoka, K. Saito, R. Saiki, I. Kumazawa, Y. Fujii. Deep learning with a convolutional neural network algorithm for automated detection of urinary tract stones using abdominal X-ray image. 2019/3/17

  4. M. Yokoyama, H. Masuda, M. Ito, Y. Waseda, S. Moriyama, M. Toide, S. Uehara, Y. Yasuda, T. Kijima, S. Yoshida, J. Ishioka, Y. Matsuoka, K. Saito, Y. Fujii. Artificial urinary sphincter implantation improves several storage and voiding symptoms in addition to urinary incontinence. 2019/3/17

  5. S. Yoshida, H. Tanaka, T. Kijima, S. Yoshida, J. Ishioka, Y. Matsuoka, K. Saito, Y. Fujii. Vesical imaging-reporting and data system (VI-RADS) for bladder cancer staging with multiparametric MRI. 2019/3/17

  6. S. Yoshida, S. Fukuda, S. Moriyama, M. Yokoyama, N. Taniguchi, K. Shinjo, M. Sugimoto, K. Saito, Y. Fujii. Holographic surgical planning of partial nephrectomy using a wearable mixed reality computer. 2019/3/17

  7. S. Yoshida, T. Takahara, C. Ishii, K. Nakagawa, K. Toda, Y. Arita, T. Kijima, M. Yokoyama, J. Ishioka, Y. Matsuoka, K. Saito, R. Yoshimura, Y. Fujii. Loco-regional radiotherapy targeting oligo-progressive lesions in castration-resistant prostate cancer patients: Intra-pelvic localized progressive lesions are the good targets. 2019/3/17

  8. T. Kijima, S. Fukuda, H. Fukushima, S. Moriyama, S. Uehara, Y. Yasuda, S. Yoshida, M. Yokoyama, J. Ishioka, Y. Matsuoka, K. Saito, Y. Fujii. Impact of multimodal salvage therapy on survival in patients with recurrent adrenocortical carcinoma. 2019/3/17

  9. H. Fukushima. M. Toide, S. Fukuda, S. Moriyama, Y. Yasuda, S. Uehara, T. Kijima, S. Yoshida, M. Yokoyama, J. Ishioka, Y. Matsuoka, K. Saito, Y. Fujii. Substratification of intermediate-risk non-muscle-invasive bladder cancer based on the prediction of high-risk recurrence: Impact of bladder neck involvement and positive urine cytology. 2019/3/17

  10. M. Toide, T. Kijima, S. Fukuda, H. Fukushima, S. Moriyama, S. Uehara, Y. Yasuda, S. Yoshida, M. Yokoyama, J. Ishioka, Y. Matsuoka, K. Saito, K. Kihara, Y. Fujii. Clinical outcomes of tetra-modality bladder preservation therapy incorporating consolidative partial cystectomy in muscle-invasive bladder cancer patients with hydronephrosis. 2019/3/17

  11. Y. Uchida, S. Yoshida, H. Shimoda, H. Tnanaka, K. Yamamoto, T. Sakamoto, K. Kaneko, T. Kijima, M. Yokoyama, J. Ishioka, Y. Matsuoka, K. Saito, Y. Fujii. Differentiation of chromophobe renal cell carcinoma and renal oncocytoma with whole-lesion ADC analysis on diffusion-weighted MRI. 2019/3/17

  12. K. Kaneko, S. Yoshida, Y. Arita, K. Yamamoto, T. Kijima, M. Yokoyama, J. Ishioka, Y. Matsuoka, K. Saito, Y. Fujii. Renal epithelioid angiomyolipoma: Incidence in a Japanese cohort and diagnostic utility of diffusion-weighted MRI. 2019/3/17

  13. T. Kijima, R. Teramatsu, S. Fukuda, H. Fukushima, S. Moriyama, S. Uehara, Y. Yasuda, S. Yoshida, M. Yokoyama, J. Ishioka, Y. Matsuoka, K. Saito, Y. Fujii. High levels of heat-shock factor 1 (HSF1) are associated with poor prognosis in muscle-invasive bladder cancer patients treated with chemoradiation-based bladder sparing protocol. 2019/3/18

  14. H. Fukushima. T. Kijima, M. Toide, S. Fukuda, S. Moriyama, Y. Yasuda, S. Uehara, S. Yoshida, M. Yokoyama, J. Ishioka, Y. Matsuoka, K. Saito, K. Kihara, Y. Fujii. Tetra-modality bladder sparing therapy can be a viable treatment option for muscle-invasive bladder cancer patients with sarcopenia. 2019/3/18

  15. H. Fukushima. K. Saito, Y. Yasuda, K. Tanabe, M. Toide, S. Fukuda, M. Yokoyama, J. Ishioka, Y. Matsuoka, D. Patil, B. Cotta, S. Patel, V. Master, I. Derweesh, Y. Fujii. Impact of sex on prognosis of non-metastatic clear cell renal cell carcinoma patients undergoing curative surgery: An inverse probability of treatment weighting analysis. 2019/3/18

  16. H. Fukushima. K. Saito, Y. Yasuda, S. Uehara, T. Kijima, S. Yoshida, M. Yokoyama, J. Ishioka, Y. Matsuoka, K. Kihara, F. Koga, T. Okuno, C. Arisawa, S. Kamata, K. Nagahama, H. Masuda, J. Yonese, Y. Kageyama, A. Noro, T. Tsujii, S. Morimoto, Y. Fujii. Obesity-specific effect of sex on prognosis of upper urinary tract urothelial carcinoma patients undergoing radical nephroureterectomy: A Japanese multicenter study. 2019/3/18

  17. S. Fukuda, K. Saito, Y. Yasuda, T. Soma, M. Toide, H. Fukushima, S. Moriyama, S. Uehara, N. Fukui, T. Kjima, S. Yoshida, M. Yokoyama, J. Ishioka, Y. Matsuoka, Y. Kageyama, Y. Fujii. Early flare-response of C-reactive protein is associated with tumor shrinkage in patients with metastatic renal cell carcinoma treated with nivolumab. 2019/3/18

  18. K. Sakamoto, M. Ito, Y. Nakanishi, M. Kataoka, H. Suzuki, K. Takemura, K. Tobisu, F. Koga. Prediction of muscle invasive bladder cancer using the vesical imaging-reporting and data system and apparent diffusion coefficient values (VI-RADS/ADC). 2019/3/15

  19. K. Takemura, M. Ito, Y. Nakanishi, M. Kataoka, K. Sakamoto, H. Suzuki, N. Iida, K. Tobisu, F. Koga. Prognostic significance of serum γ–glutamyltransferase in patients with castration-resistant prostate cancer treated with enzalutamide. 2019/3/15

  20. F. Koga, K. Sakamoto, K. Takemura, H. Suzuki, M. Kataoka, M. Ito, Y. Nakanishi, K. Tobisu. Algorithms predicting ≥pT2 and ≥pT3 upper urinary tract urothelial cancer incorporating diffusion-weighted MRI. 2019/3/17

  21. M. Ito, M. Kataoka, K. Takemura, H. Suzuki, K. Sakamoto, Y. Nakanishi, K. Tobisu, F. Koga. Outcomes of transperineal prostate biopsy using local anesthesia by trainee urologists during learning curve: Comparison with those of senior urologists. 2019/3/17

  22. M. Ito, Y. Nakanishi, M. Kataoka, K. Sakamoto, K. Takemura, H. Suzuki, N. Iida, K. Tobisu, F. Koga. Malnutrition evaluated by the controlling nutritional status (CONUT) score is associated with severe nocturia in males. 2019/3/17

  23. H. Suzuki, K. Takemura, M. Ito, Y. Nakanishi, M. Kataoka, K. Sakamoto, K. Tobisu, F. Koga. Prognostic significance of controlling nutritional status (CONUT) score in advanced urothelial carcinoma patients. 2019/3/17

  24. N. Numao, R. Fujiwara, S. Yasuoka, Y. Ishikawa, H. Inatsu, M. Ogawa, Y. Komai, T. Yuasa, S. Yamamoto, I. Fukui, J. Yonese. Comparative study of 1-day versus multiple-day administration of antimicrobial prophylaxis in radical cystectomy. 2019/3/15

  25. Y. Komai, Y. Ishikawa, S. Yasuoka, H. Inatsu, R. Fujiwara, M. Ogawa, N. Numao, T. Yuasa, S. Yamamoto, J. Yonese. The crush carving technique using a soft coagulation device – A simple method for successful laparoscopic hemi-nephrectomy without hilar clamping. 2019/3/17

  26. Y. Ishikawa, N. Numao, S. Yasuoka, R. Fujiwara, H. Inatsu, M. Ogawa, Y. Komai, T. Yuasa, S. Yamamoto, I. Fukui, J. Yonese. Combination of prebiopsy magnetic resonance imaging and systematic biopsy can efficiently predict ipsilateral negative lymph-node metastasis in prostate cancer treated with radical prostatectomy and extended pelvic lymph node dissection. 2019/3/17

  27. R. Fujiwara, N. Numao, Y. Komai, M. Ogawa, H. Inatsu, Y. Ishikawa, S. Yasuoka, T. Yuasa, S. Yamamoto, I. Fukui, J. Yonese. Effects of enhanced recovery after surgery protocols of postoperative ileus and bowel obstruction in patients undergoing radical cystectomy. 2019/3/18

  28. Y. Nakamura, Y. Kageyama, T. Soma, Y. Aoki, N. Fukui, Y. Sakai. High detection of colorectal cancer in scheduled serial total colonscopy screening after radiation therapy for prostate cancer. 2019/3/17

  29. Y. Sakai. T. Soma, Y. Nakamura, Y. Aoki, N. Fukui, Y. Kageyama. Long-term survival rates of localized prostate cancer patients treated by radical prostatectomy are significantly better than predicted life expectancy of the general population. 2019/3/18

  30. S. Yoshida, R. Takazawa, Y. Waseda, T. Tsujii. The significance of intraoperative renal pelvic urine and stone culture for patients at high risk of post-ureteroscopy systemic inflammatory response syndrome. 2019/3/16

  31. B. Cotta, K. Saito, M. Meagher, D. Patil, A. Eldefrawy, Y. Yasuda, A. Bradshaw, S. Ryan, D. Anyakora, A. Yee, J. Alksne, F. Wan, V. Master, Y. Fujii, I. Derweesh. Elevated C-reactive protein is associated with functional decline following surgery for renal cell carcinoma: Results of an international cohort study. 2019/3/18

  32. M.F. Meagher, D. Patil, K. Saito, B. Cotta, Y. Yasuda, A. Bradshaw, A. Eldefrawy, . Ryan, R. Nasseri, D. Anyakora, J. Alksne, F. Wan, Y. Fujii, V. Master, I. Derweesh. Development and validation of a novel scoring index cart (C-reactive protein, Age, Race, Tumor size) to predict renal functional decline post partial nephrectomy. 2019/3/18

米国泌尿器科学会（The 114thannual meeting of the American Urological Association, Chicago, USA）

  1. Uehara S, Matsuoka Y, Tanaka H, Yasuda Y, Moriyama S, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Saito K, Fujii Y. Does tumor contact length on MRI reflect extracapsular extension and biochemical recurrence after radical prostatectomy? 2019/5/3

  2. Toide M, Saito K, Yasuda Y, Tanabe K, Fukuda S, Fukushima H, Yokoyama M, Ishioka J, Matsuoka Y, Patil D, Cotta B, Patel S, Master V, Derweesh I, Fujii Y. Prognostic significance of C-reactive protein on survival in patients with non-metastatic papillary renal cell carcinoma: an international multi-racial study. 2019/5/3

  3. Matsuoka Y, Uehara S, Yoshida S, Tanabe K, Tanaka H, Kimura T, Moriyama S, Yasuda Y, Kijima T, Yokoyama M, Ishioka J, Saito K, Fujii Y. Who benefits additionally from concurrent systematic biopsy at the time of MRI-ultrasound fusion targeted biopsy to detect significant prostate cancer? 2019/5/4

  4. Kijima T, Teramatsu R, Fukuda S, Fukushima H, Moriyama S, Uehara S, Yasuda Y, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. High Levels of heat-shock factor 1 (HSF1) are associated with poor prognosis in muscle-invasive bladder cancer patients treated with chemoradiation-based bladder sparing protocol. 2019/5/4

  5. Yoshida S, Fukuda S, Moriyama S, Yokoyama M, Taniguchi N, Shinjo K, Sugimoto M, Saito K, Fujii Y. Holographic surgical planning using a wearable mixed reality computer. 2019/5/4

  6. Fukushima H, Saito K, Yasuda Y, Tanabe K, Toide M, Fukuda S, Yokoyama M, Ishioka J, Matsuoka Y, Patil D, Cotta B, Patel S, Master V, Derweesh I, Fujii Y. Prognostic impact of sex in non-metastatic clear cell renal cell carcinoma patients undergoing curative surgery: a multi-national study. 2019/5/4

  7. Fukushima H, Toide M, Fukuda S, Moriyama S, Yasuda Y, Uehara S, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Impact of bladder neck involvement and positive urine cytology in substratifying intermediate-risk non-muscle-invasive bladder cancer patients based on the prediction of high-risk recurrence. 2019/5/4

  8. Fukuda S, Saito K, Yasuda Y, Soma T, Toide M, Fukushima H, Moriyama S, Uehara S, Fukui N, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Kageyama Y, Fujii Y. Early flare-response of C-reactive protein is associated with efficacy of nivolumab in patients with metastatic renal cell carcinoma. 2019/5/4

  9. Toide M, Kijima T, Fukuda S, Fukushima H, Moriyama S, Uehara S, Yasuda Y, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y. Clinical outcomes of tetra-modality bladder-preserving therapy incorporating consolidative partial cystectomy in muscle-invasive bladder cancer patients with hydronephrosis. 2019/5/4

  10. Ishioka J, Kobayashi M, Fujiwara M, Kawamura N, Okuno T, Fukuda Y, Kohno T, Kawano K, Morimoto S, Uehara S, Yasuda Y, Kijima T, Yoshida S, Yokoyama M, Matsuoka Y, Saito K, Saiki R, Kumazawa I, Fujii Y. Computer-aided diagnosis with a convolutional neural network algorithm for automated detection of urinary tract stones using KUB. 2019/5/5

  11. Yoshida S. AUA/JUA International Affiliate Society Meeting 2019. Theme 1: Bladder cancer, Tri-Modality Treatment for MIBC. 2019/5/5

  12. Matsuoka Y, Tanaka H, Kimura T, Moriyama S, Uehara S, Yasuda Y, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Saito K, Fujii Y. Usefulness of apparent diffusion coefficient ratio between tumor and nontumor as an imaging biomarker for prostate cancer. 2019/5/6

  13. Yoshida S, Tanaka H, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Staging accuracy of Vesical Imaging-Reporting And Data System (VI-RADS) for bladder cancer. 2019/5/6

  14. Koga F, Sakamoto K, Takemura K, Suzuki H, Kataoka M, Ito M, Nakanishi Y, Tobisu K. Role of diffusion-weighted MRI in predicting ≥pT2 and ≥pT3 upper tract urothelial cancer. 2019/5/6

  15. Ito M, Kataoka M, Takemura K, Suzuki H, Sakamoto K, Nakanishi Y, Tobisu K, Koga F. Learning curves, cancer detection rates, and complications of transperineal prostate　biopsy under local anesthesia by trainee urologists. 2019/5/3

  16. Ito M, Nakanishi Y, Kataoka M, Sakamoto K, Takemura K, Suzuki H, Iida N, Tobisu K, Koga F. Impact of the controlling nutritional status (CONUT) score on severe nocturia in males. 2019/5/6

  17. Takemura K, Ito M, Nakanishi Y, Kataoka M, Sakamoto K, Suzuki H, Iida N, Tobisu K, Koga F. Elevated serum gamma-glutamyltransferase is an adverse prognostic factor in castration-resistant prostate cancer patients treated with enzalutamide. 2019/5/4

  18. Tanaka H, Ding X, Wang Y, Ye Y, Campbell RA, DeWitt-Foy ME, Suk-Ouichai C, Ward RD, Remer EM, Campbell SC. Significance of Radiologically Undocumented Infiltrative Renal Masses. 2019/5/3

  19. Tanaka H, Wang Y, Ye Y, Suk-Ouichai C, Palacios D, Caraballo ER, Remer EM, Li J, Abouassaly R, Campbell SC. Predicting Functional Outcomes after Partial Nephrectomy. 2019/5/5

  20. Cotta B, Saito K, Meagher M, Patil D, Eldefrawy A, Yasuda Y, Bradshaw A, Ryan S, Anyakora D, Yee A, Alksne A, Wan F, Master V, Fujii Y, Derweesh I. Elevated C-Reactive Protein is Associated with Functional Decline Following Surgery for Renal Cell Carcinoma: Results of an International Cohort Study. 2019/5/4

  21. Patel S, Meagher M, Saito K, Patil D, Bindayi A, Eldefrawy A, Ryan S, Cotta B, Yim K, Nasseri R, Hamilton Z, Yasuda Y, Fujii Y, Master V, Derweesh I. Association of Elevated C-Reactive Protein with Oncologic Outcomes in Renal Cell Carcinoma: A Multicenter Analysis. 2019/5/5

米国臨床腫瘍学会泌尿器がんシンポジウム（The 2019 Genitourinary Cancers Symposium, ASCO GU 2019, San Francisco, USA）

  1. Kijima T, Fukuda S, Fukushima H, Moriyama S, Uehara S, Yasuda Y, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y. Clinical outcomes of muscle-invasive bladder cancer patients with hydronephrosis treated with tetra-modality bladder sparing therapy incorporating consolidative partial cystectomy. 2019/2/15